Tokai Halts Phase 3 Trial of Prostate Cancer Drug Galeterone; Panel Says It’s Unlikely to Reach Primary Endpoint

Tokai Halts Phase 3 Trial of Prostate Cancer Drug Galeterone; Panel Says It’s Unlikely to Reach Primary Endpoint
Tokai Pharmaceuticals (Tokai) dropped a bombshell Tuesday when it announced it will discontinue its flagship ARMOR3-SV clinical trial, a pivotal Phase 3 study comparing the efficacy of Tokai’s prostate cancer drug galeterone to Astella Pharma’s product Xtandi (enzalutamide). Tokai said in a press release that the decision to terminate the trial was made after the trial’s independent

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *